HALO — Halozyme Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual balance sheet for Halozyme Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	741	363	336	596	143
Net Total Accounts Receivable
Net Total Receivables	91	231	234	308	441
Total Inventory
Prepaid Expenses
Total Current Assets	926	739	746	1,085	825
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	8.79	75.6	74.9	75	82.1
Net Goodwill
Net Intangible Assets
Other Long Term Assets
Total Assets	1,104	1,842	1,733	2,063	2,525
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	117	131	112	139	177
Long Term Debt
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Liabilities	907	1,672	1,649	1,700	2,477
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	197	170	83.8	364	48.8
Total Liabilities & Shareholders' Equity	1,104	1,842	1,733	2,063	2,525
Total Common Shares Outstanding